DEBBANE RAYMOND 4

What Happened

• Raymond Debbane, a director of Lexicon Pharmaceuticals (LXRX), reported derivative transactions on 2026-06-03 showing 89,312 shares acquired and 89,312 shares disposed, each at $0. The filing reflects the conversion/exercise of a derivative tied to restricted stock units (RSUs), not an open-market purchase or cash sale.

Key Details

• Transaction date: 2026-06-03; Filing date: 2026-06-04 (timely).
• Reported transactions: Exercise/conversion of derivative (code M) — 89,312 shares acquired @ $0 and 89,312 shares disposed @ $0.
• Shares owned after transaction: not specified in the provided filing details.
• Relevant footnotes:
  • F1: The RSU vests 100% on the first anniversary of the grant date.
  • F2: Each RSU represents the contingent right to receive one share of common stock.
• No cash value was reported for these entries (price = $0); the filing does not state any tax withholding, sale proceeds, or 10b5-1 plan.

Context

• This appears to be a compensation-related conversion of RSUs into shares (or related derivative accounting), rather than a market buy or sale. Such conversions are routine for vested awards and do not necessarily signal a trading decision. The filing shows both acquisition and disposition entries at $0; the filing itself doesn’t explain the mechanics (e.g., whether shares were delivered, withheld for taxes, or transferred), so no assumptions about intent or portfolio changes should be made.